Lilly grants single-patient compassionate-use access to retatrutide
Lilly has granted compassionate-use access to its obesity drug candidate retatrutide for a single patient, according to STAT’s exclusive reporting; The Readout also covers Pfizer’s lung-cancer trial results and other biotech news.